# OnCo record ux023t-cl201 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ux023t-cl201/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ux023t-cl201", "NCT02304367" ;
  schema:name "UX023T-CL201"@en ;
  schema:alternateName "UX023T CL201"@en, "Study 6"@en ;
  schema:description "This open-label study showed that an antibody blocking the phosphate-wasting hormone FGF23 raised blood phosphate to normal and helped heal fractures in adults whose soft-bone disease was driven by a small tumour that could not be located or removed, which supported Crysvita for that cancer-care use."@en ;
  schema:url <https://onco.cc/trials/ux023t-cl201/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02304367>, <https://doi.org/10.1002/jbmr.4233>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102f96a0-6e3a-4fc1-b204-34d604683af6>, <https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/burosumab/> ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/> .